Isolated renal cells and uses thereof

Abstract

The invention is directed to isolated renal cells, including tubular and erythropoietin (EPO)-producing kidney cell populations, and methods of isolating and culturing the same, as well as methods of treating a subject in need with the cell populations.

1 - 66 . (canceled) 
     
     
         67 . An isolated, enriched renal cell population derived from a mammalian kidney sample,
 wherein the isolated, enriched renal cell population is enriched for renal tubular cells; and   wherein the isolated, enriched renal cell population further comprises collecting duct cells, endocrine cells, vascular cells, and glomerular cells.   
     
     
         68 . The isolated, enriched renal cell population of  claim 67 , wherein the renal tubular cells comprise proximal tubular cells and distal tubular cells. 
     
     
         69 . The isolated, enriched renal cell population of  claim 68 , wherein the proximal tubular cells and distal tubule cells comprise approximately 90% of cells of the isolated, enriched population. 
     
     
         70 . The isolated, enriched renal cell population of  claim 67 , wherein the collecting duct cells comprise approximately 10% of cells of the isolated, enriched population. 
     
     
         71 . The isolated, enriched renal cell population of  claim 67 , wherein the renal tubular cells express of one or more of hyaluronic acid synthase 2, Vitamin D3 25-Hydroxylase, megalin, cubilin, N-cadherin, E-cadherin, Aquaporin-1, Aquaporin-2 and Aquaporin-4. 
     
     
         72 . The isolated, enriched renal cell population of  claim 67 , wherein the isolated, enriched renal cell population comprises cells that express hyaluronic synthase-2. 
     
     
         73 . The isolated, enriched renal cell population of  claim 67 , wherein the renal tubular cells are capable of albumin uptake. 
     
     
         74 . The isolated, enriched renal cell population of  claim 67 , wherein the isolated, enriched renal cell population comprises cells that are hypoxia-resistant. 
     
     
         75 . The isolated, enriched renal cell population of  claim 67 , wherein the isolated, enriched renal cell population comprises cells that are iodixanol-resistant 
     
     
         76 . The isolated, enriched renal cell population of  claim 67 , wherein the mammalian kidney sample is a human kidney sample. 
     
     
         77 . The isolated, enriched renal cell population of  claim 76 , wherein the human kidney sample is a kidney biopsy sample. 
     
     
         78 . An implantable construct comprising the isolated, enriched renal cell population of  claim 67  and a biomaterial. 
     
     
         79 . The implantable construct of  claim 78 , wherein the biomaterial is a polymeric matrix. 
     
     
         80 . The implantable construct of  claim 78 , wherein the biomaterial is a scaffold. 
     
     
         81 . The implantable construct of  claim 78 , wherein the biomaterial is configured as a liquid hydrogel suspension. 
     
     
         82 . The implantable construct of  claim 78 , wherein the biomaterial is configured as a porous foam. 
     
     
         83 . A pharmaceutical composition comprising the isolated, enriched renal cell population of  claim 67  and a pharmaceutically acceptable carrier.